ARS PharmaceuticalsNASDAQ: SPRY

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

04 December 2020

Next earnings report:

21 March 2025

Last dividends:

N/A

Next dividends:

N/A
$1.30 B
-25%vs. 3y high
76%vs. sector
-vs. 3y high
-vs. sector
-25%vs. 3y high
87%vs. sector
505.23
-84%vs. 3y high
98%vs. sector

Price

after hours | Wed, 20 Nov 2024 22:14:02 GMT
$13.35-$0.55(-3.96%)

Dividend

No data over the past 3 years
$2.07 M$25.58 M
$2.07 M-$19.13 M

Analysts recommendations

Institutional Ownership

SPRY Latest News

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
zacks.com13 November 2024 Sentiment: NEGATIVE

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.16 per share a year ago.

ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript
seekingalpha.com13 November 2024 Sentiment: POSITIVE

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Alex Straus - Investor Relations Richard Lowenthal - Co-Founder, President and CEO Eric Karas - Chief Commercial Office Kathleen Scott - CFO Justin Chakma - Chief Business Officer Conference Call Participants Josh Schimmer - Cantor Fitzgerald Ryan Deschner - Raymond James Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Operator Good day, and welcome to the ARS Pharmaceuticals Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
accesswire.com03 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
accesswire.com02 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Here's Why 'Trend' Investors Would Love Betting on ARS Pharmaceuticals, Inc. (SPRY)
zacks.com30 October 2024 Sentiment: POSITIVE

ARS Pharmaceuticals, Inc. (SPRY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
accesswire.com27 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Shareholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
accesswire.com26 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Shareholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
accesswire.com20 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Shareholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
accesswire.com18 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
accesswire.com13 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

What type of business is ARS Pharmaceuticals?

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

What sector is ARS Pharmaceuticals in?

ARS Pharmaceuticals is in the Healthcare sector

What industry is ARS Pharmaceuticals in?

ARS Pharmaceuticals is in the Biotechnology industry

What country is ARS Pharmaceuticals from?

ARS Pharmaceuticals is headquartered in United States

When did ARS Pharmaceuticals go public?

ARS Pharmaceuticals initial public offering (IPO) was on 04 December 2020

What is ARS Pharmaceuticals website?

https://ars-pharma.com

Is ARS Pharmaceuticals in the S&P 500?

No, ARS Pharmaceuticals is not included in the S&P 500 index

Is ARS Pharmaceuticals in the NASDAQ 100?

No, ARS Pharmaceuticals is not included in the NASDAQ 100 index

Is ARS Pharmaceuticals in the Dow Jones?

No, ARS Pharmaceuticals is not included in the Dow Jones index

When was ARS Pharmaceuticals the previous earnings report?

No data

When does ARS Pharmaceuticals earnings report?

The next expected earnings date for ARS Pharmaceuticals is 21 March 2025